To the Editor: The recent case report by Chow and colleagues raises questions about the causal link between black cohosh use and hepatotoxicity.1 The authors state that the patient had no history of “significant alcohol consumption”, but a presumably related adverse drug reaction report available from the Therapeutic Goods Administration reveals her alcohol use was “3–4 units [of] alcohol per day, [with] 1–2 alcohol-free days per week”.2 Alcohol misuse is a known risk factor for severe liver disease, as is gastric bypass surgery for obesity,3 also in the patient’s history. Unfortunately, because histological examination of the liver 6 weeks after first presentation found no recognisable residual hepatocytes, the diagnoses of alcoholic steatohepatitis, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis cannot be excluded. Without this, the specific conclusion of the liver biopsy that the “Massive hepatocellular necrosis [was] associated with herbal medication”2 cannot be substantiated.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Chow ECY, Teo M, Ring JA, Chen JW. Liver failure associated with the use of black cohosh for menopausal symptoms. Med J Aust 2008; 188: 420-422. <MJA full text>
- 2. Australian Government Department of Health and Ageing Therapeutic Goods Administration. Public case detail for case number 220336, recorded as reported to the Adverse Drug Reactions Unit, 25 July 2006.
- 3. Ong JP, Elariny H, Collantes R, et al. Predictors of non-alcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 2005; 15: 310-315.
- 4. European Medicines Agency, Committee on Herbal Medicinal Products (HMPC). Assessment of case reports connected to herbal medicinal products containing Cimicifugae racemosae rhizoma (black cohosh, root). London: EMEA, 2007. http://www.emea.europa. eu/pdfs/human/hmpc/26925806en.pdf (accessed Oct 2008).
- 5. Levitsky J, Alli TA, Wisecarver J, Sorrell MF. Erratum: Fulminant liver failure associated with the use of black cohosh. Dig Dis Sci 2008; 53: 869.
- 6. Grant SM, Beck R v Pharmavite, Neutraceutical (2006). Case: 8:05-cv-00066-LES-TDT. United States District Court for the District of Nebraska. http://www.ahpa.org/Portals/0/pdfs/06_0908_BlackCohosh_NebraskaDistrictCt.pdf (accessed Oct 2008).
- 7. Naser B, Liske E. Adverse liver reactions to black cohosh: are they accurately reported? Climacteric 2008; 11 Suppl 2: 114.
We are both employed by Schaper and Brümmer, manufacturer of black cohosh preparations.